Ovarian dysgerminoma: a retrospective analysis of results of treatment, sites of treatment failure, and radiosensitivity.
Thirty-five patients with a diagnosis of pure ovarian dysgerminoma underwent assessment at our institution between 1950 and 1984. The median age of these patients was 21 years (range, 8 to 41 years). The surgical pathologic stages of the tumors were as follows: stage IA1 in 18 patients, stage IA2 in 2, stage IB1 in 2, stage IC in 1, stage IIB in 2, stage III in 9, and stage IV in 1. The overall survival at 5, 10, and 20 years was 94.3%, 82.9%, and 82.9%, respectively, for all 35 patients and 100%, 83.9%, and 83.9%, respectively, for the 18 patients with stage IA1 lesions. The maximum interval from diagnosis to relapse was 3.7 years. All patients were under surveillance for a minimum of 2 years (median follow-up, 15.9 years). Of the 18 patients with stage IA1 disease, 16 did not receive prophylactic radiation therapy to the para-aortic lymph nodes, and in 6 of the 16 (38%) recurrent disease developed in this region. Five of these patients were salvaged with radiation therapy and one with radiation therapy and subsequent chemotherapy. No definite correlation was noted between the size or mass of the resected unilateral encapsulated tumor and the risk of development of recurrent disease. For patients with stage IA1 dysgerminoma who have undergone unilateral oophorectomy, two treatment options seem reasonable: (1) observation, with radiation therapy reserved for subsequent recurrence, or (2) prophylactic radiation therapy (2,000 cGy) to para-aortic and ipsilateral common iliac lymph nodes, which would preserve fertility.
Buskirk
S J
SJ
Division of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224.
Schray
M F
MF
Podratz
K C
KC
Lee
R A
RA
Stanhope
C R
CR
Gaffey
T A
TA
Weber
F C
FC
Earle
J D
JD
Naessens
J M
JM
Malkasian
G D
GD
D000293:Adolescent; D000328:Adult; D002648:Child; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000532:radiotherapy; D010051:Ovarian Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies